EDF-1 contributes to the regulation of nitric oxide release in VEGF-treated human endothelial cells

European Journal of Cell Biology

Volumn 89, Issue 9, 2010, Pages 654-660

  Leidi, Marzia ^a   Mariotti, Massimo ^a   Maier, Jeanette A M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

EDF 1; Human endothelial cells; Nitric oxide; VEGF

Indexed keywords

CALMODULIN BINDING PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; OKADAIC ACID; PHOSPHATASE; PROTEIN ENDOTHELIAL DIFFERENTIATION RELATED FACTOR 1; SERINE; THREONINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME RELEASE; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION;

EID: 77954955353     PISSN: 01719335     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcb.2010.05.001     Document Type: Article

References (42)

1. Albrecht E.W., Stegeman C.A., Heeringa P., Henning R.H., van Goor H. Protective role of endothelial nitric oxide synthase. J. Pathol. 2003, 199:8-17.
2. Ballabio E., Mariotti M., De Benedictis L., Maier J.A. The dual role of endothelial differentiation-related factor-1 in the cytosol and nucleus: modulation by protein kinase A. Cell. Mol. Life Sci. 2004, 61:1069-1074.
3. Blanes M.G., Oubaha M., Rautureau Y., Gratton J.P. Phosphorylation of tyrosine 801 of vascular endothelial growth factor receptor-2 is necessary for Akt-dependent endothelial nitric-oxide synthase activation and nitric oxide release from endothelial cells. J. Biol. Chem. 2007, 282:10660-10669.
4. Bredt D.S., Snyder S.H. Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:682-685.
5. Brendel C., Gelman L., Auwerx J. Multiprotein bridging factor-1 (MBF-1) is a cofactor for nuclear receptors that regulate lipid metabolism. Mol. Endocrinol. 2002, 16:1367-1377.
6. Busk P.K., Wulf-Andersen L., Strøm C.C., Enevoldsen M., Thirstrup K., Haunsø S., et al. Multiprotein bridging factor 1 cooperates with c-Jun and is necessary for cardiac hypertrophy in vitro. Exp. Cell Res. 2003, 286:102-114.
7. Butt E., Bernhardt M., Smolenski A., Kotsonis P., Fröhlich L.G., Sickmann A., et al. Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. J. Biol. Chem. 2000, 275:5179-5187.
8. Chen Z., Peng I., Sun W., Su M., Hsu P., Fu Y., et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ. Res. 2009, 104:496-505.
9. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
10. Dimmeler S., Dernbach E., Zeiher A.M. Phosphorylation of the endothelial nitric oxide synthase at Ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett. 2000, 477:258-262.
11. Dragoni I., Mariotti M., Consalez G.G., Soria M.R., Maier J.M. EDF-1, a novel gene product down-regulated in human endothelial cell differentiation. J. Biol. Chem. 1998, 273:31119-31124.
12. Fukumura D., Gohongi T., Kadambi A., Izumi Y., Ang J., Yun C.O., et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:2604-2609.
13. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399:597-601.
14. García C., Aranda J., Arnold E., Thébault S., Macotela Y., López-Casillas F., et al. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. J. Clin. Invest. 2008, 118:2291-2300.
15. Gélinas D.S., Bernatchez P.N., Rollin S., Bazan N.G., Sirois M.G. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br. J. Pharmacol. 2002, 137:1021-1030.
16. Gonzalez E., Kou R., Lin A.J., Golan D.E., Michel T. Subcellular targeting and agonist-induced site-specific phosphorylation of endothelial nitric-oxide synthase. J. Biol. Chem. 2002, 277:39554-39560.
17. Gonzalez E., Nagiel A., Lin A.J., Golan D.E., Michel T. Small interfering RNA-mediated down-regulation of caveolin-1 differentially modulates signaling in endothelial cells. J. Biol. Chem. 2004, 279:40659-40669.
18. Greif D.M., Kou R., Michel T. Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: evidence for crosstalk between phosphorylation sites. Biochemistry 2002, 41:15845-15853.
19. Hashimoto A., Miyakoda G., Hirose Y., Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006, 189:350-357.
20. He H., Venema V.J., Gu X., Venema R.C., Marrero M.B., Caldwell R.B. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J. Biol. Chem. 1999, 274:25130-25135.
21. Hoffmann A., Gloe T., Pohl U. Hypoxia-induced upregulation of eNOS gene expression is redox-sensitive: a comparison between hypoxia and inhibitors of cell metabolism. J. Cell. Physiol. 2001, 188:33-44.
22. Holm P.W., Slart R.H., Zeebregts C.J., Hillebrands J.L., Tio R.A. Atherosclerotic plaque development and instability: a dual role for VEGF. Ann. Med. 2009, 41(4):257-264.
23. Hood J.D., Meininger C.J., Ziche M., Granger H.J. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 1998, 274:H1054-H1058.
24. Kone B.C. Protein-protein interactions controlling nitric oxide synthases. Acta Physiol. Scand. 2000, 168:27-31.
25. Leidi M., Mariotti M., Maier J.A.M. Transcription coactivator EDF-1 is required for PPARγ-stimulated adipogenesis. Cell. Mol. Life Sci. 2009, 66(16):2733-2742.
26. Leidi M., Mariotti M., Maier J.A.M. The effects of silencing EDF-1 in human endothelial cells. Atherosclerosis 2010, 10.1016/j.atherosclerosis.2010.01.022.
27. Liu Q.X., Jindra M., Ueda H., Hiromi Y., Hirose S. Drosophila MBF1 is a co-activator for Tracheae Defective and contributes to the formation of tracheal and nervous systems. Development 2003, 130:719-728.
28. Mariotti M., De Benedictis L., Avon E., Maier J.A.M. Interaction between endothelial differentiation-related factor-1 and calmodulin in vitro and in vivo. J. Biol. Chem. 2000, 275:24047-24051.
29. Michell B.J., Chen Z., Tiganis T., Stapleton D., Katsis F., Power D.A., Sim A.T., Kemp B.E. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J. Biol. Chem. 2001, 276(21):17625-17628.
30. Michell B.J., Harris M.B., Chen Z.P., Ju H., Venema V.J., Blackstone M.A., et al. Identification of regulatory sites of phosphorylation of the bovine endothelial nitric-oxide synthase at serine 617 and serine 635. J. Biol. Chem. 2002, 277:42344-42351.
31. Nakhaei-Nejad M., Zhang Q.X., Murray A.G. Endothelial IQGAP1 regulates efficient lymphocyte transendothelial migration. Eur. J. Immunol. 2010, 40:204-213.
32. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling in control of vascular function. Nat. Rev. Mol. Cell. Biol. 2006, 7:359-371.
33. Papapetropoulos A., García-Cardeña G., Madri J.A., Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 1997, 100:3131-3139.
34. Reihill J.A., Ewart M.A., Hardie D.G., Salt I.P. AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production. Biochem. Biophys. Res. Commun. 2007, 354:1084-1088.
35. Rosenfeld C.R., Chen C., Roy T., Liu X. Estrogen selectively up-regulates eNOS and nNOS in reproductive arteries by transcriptional mechanisms. J. Soc. Gynecol. Investig. 2003, 10:205-215.
36. 2+/calmodulin-dependent protein kinase II in endothelial NO production and endothelium-dependent relaxation. Am. J. Physiol. Heart Circ. Physiol. 2003, 284:H2311-2319.
37. 2+) values for calmodulin binding and enzyme activation. J. Biol. Chem. 2009, 284(18):11892-11899.
38. Urbich C., Reissner A., Chavakis E., Dernbach E., Haendeler J., Fleming I., et al. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J. 2002, 16:706-708.
39. van der Zee R., Murohara T., Luo Z., Zollmann F., Passeri J., Lekutat C., Isner J.M. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997, 95(4):1030-1037.
40. van Haperen R., de Waard M., van Deel E., Mees B., Kutryk M., van Aken T., et al. Reduction of blood pressure, plasma cholesterol, and atherosclerosis by elevated endothelial nitric oxide. J. Biol. Chem. 2002, 27:48803-48807.
41. Yan G., You B., Chen S.P., Liao J.K., Sun J. Tumor necrosis factor-alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-alpha 1. Circ. Res. 2008, 103:591-597.
42. Zhang Y., Lee T.S., Kolb E., Sun K., Lu X., Sladek F.M., et al. AMP-activated protein kinase is involved in endothelial NO synthase activation in response to shear stress. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1281-1287.